An experimental Amgen Inc. drug that targets a specific genetic mutation shrank tumors in 32% of advanced lung cancer patients and 7% of those with colon cancer, according to data from an early-stage trial.
FRANKFURT (Reuters) – AstraZeneca’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, […]
Bristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study
Analysts, Blockbusters, Clinical Data, Clinical Trials, Combination Therapies, European Society for Medical Oncology (ESMO), Immunotherapies, Kidney Cancer, Progression-Free Survival (PFS), R&D, Renal Cell Carcinoma (RCC), Researchers, TherapeuticsBristol Myers’ Opdivo with Exelixis drug cuts kidney cancer death risk: study NEW YORK (Reuters) – Bristol Myers Squibb Co’s cancer immunotherapy Opdivo in combination with Exelixis Inc’s Cabometyx reduced […]
Roche said two-thirds of spinal muscular atrophy (SMA) patients taking the Swiss drugmaker’s newly approved medicine Evrysdi have previously received rival treatments Zolgensma from Novartis or Biogen’s Spinraza.
Scientists from across the globe expressed concern over the lack of available data that could provide a key to how well the world’s first Covid-19 vaccine – approved in Russia without going through Phase III testing – could work stemming the rise of the novel coronavirus.
The U.S. Food and Drug Administration approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc. for spinal muscular atrophy in adults and children two months and above.
Special Feature: Medical Cannabis Continues To Grow
Analysts, August 2020, Canada, Cannabidiol (CBD), Cannabis, Colorado, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Doctors, Dravet syndrome, Drug Schedules, Europe, Florida, Healthcare Communications Agencies, Healthcare Communications Networks, Issue Archives, Lennox-Gastaut Syndrome (LGS), Marketing & Advertising, Med Ad News, Medical Cannabis, Minnesota, New Jersey, New Mexico, Oklahoma, Schedule I Drugs, Schedule II Drugs, Schedule III Drugs, Special Features, Synthesized Molecules, Tetrahydrocannabinol (THC), United States, WashingtonThe medical cannabis market in the United States, even with all of its restrictions, continues to be a fertile area not only for dispensaries, but pharma companies developing cannabis-derived drugs; and proponents say further growth can be generated by educating physicians about medical cannabis.
Top 200 Medicines Annual Report: Climbing Mount Humira
Analysts, August 2020, Autoimmune Diseases, Biologics, Blockbusters, Checkpoint Inhibitors, Chemotherapy, FDA, Healthcare Physicians, Human Anti-CD38 Monoclonal Antibody, Immuno-oncology, Issue Archives, Med Ad News, Metastatic squamous cell carcinoma of the esophagus, Multiple myeloma, Oncology, PD-1/PD-L1 inhibitors, Therapeutics, Top 200 MedicinesWhile Humira remains the best-selling prescription product worldwide, Keytruda has risen to the No. 2 global rank and is on track to eventually claim the top spot.
EVERSAN and Havas Health & You announced an exclusive strategic partnership agreement, inclusive of data, analytics and predictive platforms, combined with commercialization services, to offer to health and wellness clients worldwide.
The U.S. government set a benchmark for COVID-19 vaccine pricing that will likely pressure other manufacturers to set similar prices, industry analysts told Reuters.